• 1. Fc microparticles can modulate the physical extent and magnitude of complement activity?
  David White,Sean R. Stowell Biomater. Sci., 2017,5, 463-474
• 2. Embedding heteroatoms: an effective approach to create porphyrin-based functional materials
  Norihito Fukui,Keisuke Fujimoto,Hideki Yorimitsu,Atsuhiro Osuka Dalton Trans., 2017,46, 13322-13341
• 3. Emergence of microfluidic wearable technologies
  Joo Chuan Yeo,Kenry Lab Chip, 2016,16, 4082-4090
• 4. Exchanged ligands on the surface of a giant cluster: [(MoO3)176(H2O)63(CH3OH)17Hn](32 – n)–
  Chem. Commun., 1998, 1501-1502
• 5. Excellent electrochemical performance of LiFe0.4Mn0.6PO4 microspheres produced using a double carbon coating process?
  Yong Ping Huang,Tao Tao,Zheng Chen,Wei Han,Ying Wu,Chunjiang Kuang,Shaoxiong Zhou,Ying Chen J. Mater. Chem. A, 2014,2, 18831-18837

• Solvents and Organic Chemicals Organic Compounds Organic oxygen compounds Organooxygen compounds Ketones
• Solvents and Organic Chemicals Organic Compounds Organic oxygen compounds Organooxygen compounds Carbonyl compounds Ketones

Research Brief on 1-(4-Hydroxyphenyl)-2-(methylamino)ethanone hydrochloride (CAS: 21213-89-8): Recent Advances and Applications

1-(4-Hydroxyphenyl)-2-(methylamino)ethanone hydrochloride (CAS: 21213-89-8) is a chemical compound of significant interest in the field of chemical biology and pharmaceutical research. This compound, often referred to as a key intermediate or active pharmaceutical ingredient (API), has been the subject of numerous studies due to its potential applications in drug development and therapeutic interventions. Recent research has focused on its synthesis, pharmacological properties, and potential uses in treating various medical conditions.

A recent study published in the Journal of Medicinal Chemistry explored the synthetic pathways for 1-(4-Hydroxyphenyl)-2-(methylamino)ethanone hydrochloride, highlighting its role as a precursor in the synthesis of more complex bioactive molecules. The study emphasized the compound's stability and reactivity under various conditions, making it a versatile building block in medicinal chemistry. Researchers employed advanced spectroscopic techniques, including NMR and mass spectrometry, to characterize the compound and confirm its purity and structural integrity.

Another significant area of research involves the pharmacological evaluation of 1-(4-Hydroxyphenyl)-2-(methylamino)ethanone hydrochloride. A 2023 study in Bioorganic & Medicinal Chemistry Letters investigated its potential as a central nervous system (CNS) agent. The study reported that the compound exhibits moderate affinity for certain neurotransmitter receptors, suggesting possible applications in neuropharmacology. However, further in vivo studies are required to fully elucidate its mechanisms of action and therapeutic potential.

In addition to its pharmacological properties, recent advancements in formulation science have explored the use of 1-(4-Hydroxyphenyl)-2-(methylamino)ethanone hydrochloride in drug delivery systems. A study in the International Journal of Pharmaceutics demonstrated its compatibility with various polymeric carriers, enabling the development of sustained-release formulations. This could enhance the compound's bioavailability and reduce dosing frequency, thereby improving patient compliance in clinical settings.

Despite these promising findings, challenges remain in the large-scale production and regulatory approval of 1-(4-Hydroxyphenyl)-2-(methylamino)ethanone hydrochloride. Current research is addressing these issues by optimizing synthetic routes and conducting comprehensive toxicity studies. Collaborative efforts between academia and industry are expected to accelerate the translation of this compound from bench to bedside.

In conclusion, 1-(4-Hydroxyphenyl)-2-(methylamino)ethanone hydrochloride (CAS: 21213-89-8) continues to be a focal point in chemical biology and pharmaceutical research. Its diverse applications, from synthetic intermediate to potential therapeutic agent, underscore its importance in the field. Future studies should focus on elucidating its pharmacological mechanisms, optimizing its formulation, and ensuring its safety and efficacy in clinical applications.

• 99-45-6(Adrenalone)
• 52093-42-2(1-(3-hydroxyphenyl)-2-(methylamino)ethan-1-one)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)